GlassScriptPhysician profile
Laura Romundstad
NPI 1255757209
$10,185.05
in general payments reported to CMS, 2019-2025
59 companies · $4,237 in 2025
The $4,237 reported for 2025 was more than what 98% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,125 · 2023: $1,545 · 2024: $3,278 · 2025: $4,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,798 · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,798.10 |
| Education | $261.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,328.66 | 2021-2025 | |
| Janssen Biotech, INC. | $851.43 | 2023-2025 | Darzalex, Erleada, Talvey |
| Novartis Pharmaceuticals Corporation | $737.36 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $529.41 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $507.46 | 2023-2025 | Ninlaro, Fruzaqla, Iclusig |
| Incyte Corporation | $491.04 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Genentech USA, INC. | $441.53 | 2023-2025 | Polivy, Tecentriq, Lunsumio |
| Celgene Corporation | $387.80 | 2023-2025 | Reblozyl, Pomalyst |
| Pfizer INC. | $375.01 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $360.16 | 2023-2025 | Calquence, Imfinzi, Lynparza |
| Daiichi Sankyo INC. | $233.99 | 2023-2025 | Enhertu, Datroway |
| E.R. Squibb & Sons, L.L.C. | $227.17 | 2023-2025 | Opdivo, Opdualag, Krazati |
| Lilly USA, LLC | $219.56 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $205.26 | 2023-2025 | |
| Glaxosmithkline, LLC. | $194.18 | 2024-2025 | Jemperli, Ojjaara, Blenrep |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $176.39 | 2025 | Brukinsa, Tevimbra |
| Exelixis INC. | $175.31 | 2023-2025 | Cabometyx |
| Csl Behring | $171.70 | 2024-2025 | Hizentra |
| Sobi, INC | $162.75 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $155.45 | 2023-2025 | Libtayo, Lynozyfic |
| Eisai INC. | $152.66 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $137.11 | 2024-2025 | Onivyde, Somatuline Depot |
| Array Biopharma INC | $123.20 | 2023-2025 | Braftovi, Mektovi, Tukysa |
| Deciphera Pharmaceuticals INC. | $116.81 | 2024-2025 | Qinlock, Tgct, Romvimza |
| Stemline Therapeutics INC. | $116.34 | 2023-2025 | Orserdu |
| Aveo Pharmaceuticals, INC. | $107.29 | 2024-2025 | |
| Beigene USA, INC. | $106.64 | 2024-2025 | Brukinsa, Tevimbra |
| Astellas Pharma US INC | $96.45 | 2023-2025 | Xtandi, Xospata |
| Seagen INC. | $90.14 | 2023 | Adcetris, Padcev, Tukysa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.82 | 2023-2025 | Gilotrif |
| Alexion Pharmaceuticals, INC. | $82.33 | 2023-2024 | Ultomiris |
| Pharmaessentia USA Corporation | $75.25 | 2023-2025 | Besremi |
| Genmab U.S., INC. | $75.19 | 2023-2025 | Epkinly |
| Pharmacosmos Therapeutics INC. | $72.31 | 2023-2025 | Monoferric |
| Blueprint Medicines Corporation | $71.79 | 2023-2025 | Ayvakit |
| Kite Pharma, INC. | $71.15 | 2023-2025 | Yescarta |
| Sumitomo Pharma America, INC. | $52.85 | 2023-2025 | Orgovyx |
| Mirati Therapeutics, INC. | $50.67 | 2023-2024 | Krazati |
| Adaptive Biotechnologies Corporation | $48.67 | 2024-2025 | Clonoseq |
| Puma Biotechnology, INC. | $46.20 | 2023-2025 | |
| Servier Pharmaceuticals LLC | $42.64 | 2024-2025 | |
| Coherus Oncology, INC. | $41.50 | 2024 | |
| Rigel Pharmaceuticals, INC. | $32.69 | 2023-2024 | Tavalisse, Rezlidhia |
| Iovance Biotherapeutics, INC. | $32.38 | 2024-2025 | Amtagvi |
| Emd Serono, INC. | $31.35 | 2025 | |
| Karyopharm Therapeutics INC. | $29.20 | 2025 | Xpovio |
| Jazz Pharmaceuticals INC. | $28.20 | 2024 | |
| Genzyme Corporation | $25.07 | 2025 | |
| Recordati_rare_diseases_inc. | $24.83 | 2025 | Enjaymo |
| Acrotech Biopharma INC. | $24.17 | 2023 | Beleodaq |
| Morphosys, US INC. | $22.91 | 2023 | Monjuvi |
| Kyowa Kirin, INC. | $21.82 | 2025 | |
| Immunogen, INC. | $20.29 | 2024 | Elahere |
| Apellis Pharmaceuticals, INC. | $19.05 | 2023 | Empaveli |
| Gilead Sciences, INC. | $17.43 | 2025 | Trodelvy |
| Adc Therapeutics America, INC. | $16.72 | 2024 | |
| Fennec Pharmaceuticals, INC. | $16.61 | 2025 | Fyarro |
| Taiho Oncology, INC. | $15.55 | 2024 | |
| Agios Pharmaceuticals, INC. | $14.15 | 2025 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Romundstad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.